1490 O’Brien Drive
About TeneoBio, Inc.
TeneoBio, Inc. is a biotechnology company that is developing a new class of biologics, Human Heavy Chain Antibodies (UniAbs™), as therapeutics against cancer, autoimmunity, and infectious diseases. TeneoBio has several products in pre-clinical development for the treatment of multiple myeloma, prostate cancer, immune disorders and AIDS.
CEO: Roland Buelow
CFO: Stephen Dance
CMO: Ben Buelow
CSO: Wim van Schooten
CBO: Omid Vafa
9 articles with TeneoBio, Inc.
Teneobio and Selexis Expand Relationship with Three Commercial License Agreements for Multi-specific Antibody Candidates in Oncology
Selexis SA and Teneobio, Inc. announced that they have signed three commercial license agreements for the development of Teneobio’s Human Heavy-Chain Antibodies, a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer.
AbbVie and Teneobio Announce a Strategic Transaction to Develop a New Treatment for Multiple Myeloma
AbbVie, Teneobio, Inc. and its affiliate TeneoOne, Inc. announced that they have entered a global strategic transaction to develop and commercialize TNB-383B, a BCMA-targeting immunotherapeutic for the potential treatment of multiple myeloma.
AbbVie is taking a $90 million plunge into B-cell maturation antigen (BCMA)-targeting immunotherapeutics against multiple myeloma in a collaborative deal with Menlo Park, Calif.-based Teneobio, Inc.
Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno-Oncology, Multispecific Antibodies
TESARO will have exclusive licenses to the antibodies for clinical development and commercialization on a global basis.
TeneoBio’s Next Gen Multivalent anti-BCMAxCD3, TNB-383B, and Anti-BCMA UniDabs for CAR T-Cell Therapy of Multiple Myeloma Highlighted at the American Society of Hematology
Data showed results from the application of TeneoBio’s suite of technologies in the generation of the lead therapeutic candidate.
TeneoBio, Inc. And Poseida Therapeutics Announce License Agreement For The Use Of Unidab In CAR T-Cell Therapy
TeneoBio, Inc.’s Next Generation T Cell Redirection Antibody Platform For Cancer Biotherapeutics Offers Prospects Of Reducing Cytokine Release